CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...